DONATE

The UK's New Celiac Disease Guidelines Explained: What Canadians Should Know

What Do the New Guidelines Mean for Canadians?

Written by Alyssa Ramuscak, Research Analyst for Celiac Canada,  July 20, 2026

The British Society of Gastroenterology recently released updated clinical guidelines for diagnosing and managing celiac disease in adults.​(1​) One of the most talked-about changes is the introduction of a non-biopsy diagnostic pathway for selected adults. Under these new guidelines, some adults may be diagnosed without an intestinal biopsy. However, this recommendation does not apply to everyone.  

In the guidelines, it outlines that in selected adults with symptoms suggestive of celiac disease, a gastroenterologist may diagnose celiac disease without an intestinal biopsy if the individual has tissue transglutaminase antibodies (IgA-tTG) that are at least 10 times the upper limit of normal. The guidelines also emphasized that this pathway is optional and should be made by a specialist through individualized discussion and shared decision-making with the patient.  

This recommendation was developed following a comprehensive review of the available scientific evidence by an international panel of gastroenterologists, dietitians, and patient representatives. The panel evaluated the quality and certainty of the evidence before reaching consensus on each recommendation. 

While current findings are promising, the guidelines did note that only ~20-30% of adults with raised serology levels will reach an IgA-tTG titre of 10 times the upper limit of normal threshold, meaning this approach only applies to a minority of patients.​1​ Furthermore, they emphasized that a non-biopsy approach would not be appropriate for several population groups, including asymptomatic cases, older adults, or individuals with a recent diagnosis of another autoimmune disease which may falsely elevate tTG levels. 

Why hasn’t Canada adopted this approach? 

Despite the growing evidence supporting a non-biopsy approach, North American guidelines continue to recommend an intestinal biopsy to confirm the diagnosis of celiac disease in adults.​(2,3)​ This difference does not necessarily reflect disagreement with the evidence. Rather, it reflects differences in healthcare systems, laboratory testing, and how guideline groups weigh the available evidence when developing clinical recommendations.  

One important consideration is that not all serological blood tests perform equally. Different laboratories may use different testing methods, meaning a result of 10 times the upper limit of normal from one laboratory may not be directly comparable to the same results from another. For example, one large international study found considerable variation in the performance of TTG assays across research and clinical laboratories, with reported sensitivity ranging from 63% to 93% and specificity ranging from 96% to 100%.​(4​) Recognizing this variability, the British guidelines emphasize non-biopsy approaches should only be used in laboratories that use validated TTG assays and participate in quality assurances programs. In other words, the success of this approach depends not only on the blood test itself but also on the confidence that laboratory testing is accurate, standardized, and consistently performed. 

In addition to laboratory testing, North American guidelines have noted that much of the available literature on non-biopsy approaches have been based on children and to a less degree adults.​(2​) In one multicentre international study of adults, it was found that an IgA-tTG level greater than 10 times the upper limit of normal had a positive predictive value of 95% for celiac disease.​(5​) Given the life-long treatment implications of a gluten-free diet, including the challenges like the cost of gluten-free foods and social restriction, this may be unacceptably low.​(2,3​) 

What does this mean for Canadians? 

For now, the diagnosis of celiac disease in Canada remains unchanged. Adults with suspected celiac disease are generally advised to undergo an upper endoscopy with small intestinal biopsies to confirm the diagnosis.(​2,3​)

It’s important to remember that an intestinal biopsy remains an important diagnostic tool – in Europe and North America! Biopsies provide confirmation of celiac disease and are important in cases where antibody levels may not be high enough, blood tests are inconclusive or conflicting, someone is asymptomatic, or when there may be another possible diagnosis. 

While the jury may still be out on a non-biopsy approach to diagnosing celiac disease in North America, guidelines remain the same for the following: 

  • Don’t start a gluten-free diet before testing. Diagnostic tools only work best when someone is consistently eating gluten. 
  • Speak with your healthcare provider if you suspect celiac disease. Your healthcare provider can help you get the proper bloodwork screening, rule out other causes, and provide necessary referrals. 
  • Above all, follow the current Canadian diagnostic pathway. If future Canadian guidelines change, your healthcare team will guide you through this process. 

The publication of the updated British guidelines represents an important step in the evolving evidence surrounding the diagnosis of celiac disease. As more research becomes available and laboratory testing improves, North American guideline groups will continue to evaluate whether a non-biopsy approach can be safely adopted. 

Regardless of the diagnostic pathway, the goal remains the same: to ensure that people with celiac disease receive an accurate diagnosis so they can begin treatment with confidence. 

 

To read more about the 2026 British Society of Gastroenterology guidelines on diagnosis and management of adult coeliac disease, see: 

 

Penny HA et al. The 2026 British Society of Gastroenterology guidelines on the diagnosis and management of adult coeliac disease. Gut 2026;0:1-28. Doi:10.1136/gutjnl-2025-337747 

https://www.bsg.org.uk/clinical-resource/bsg-guidelines-adult-coeliac-disease

References 

​​1. Penny HA, Shiha MG, Raju SA, et al. The 2026 British Society of Gastroenterology guidelines on the diagnosis and management of adult coeliac disease. Gut. Published online July 12, 2026:gutjnl-2025-337747. doi:10.1136/gutjnl-2025-337747 

​2. Rubio-Tapia A, Hill ID, Semrad C, et al. American College of Gastroenterology Guidelines Update: Diagnosis and Management of Celiac Disease. American Journal of Gastroenterology. 2023;118(1):59-76. doi:10.14309/ajg.0000000000002075 

​3. Blom JJ, Gidrewicz D, Turner J, Duerksen DR, Pinto-Sánchez MI. Diagnosis and management of celiac disease. Can Med Assoc J. 2025;197(38):E1258-E1265. doi:10.1503/cmaj.230091 

​4. Li M, Yu L, Tiberti C, et al. A Report on the International Transglutaminase Autoantibody Workshop for Celiac Disease. Am J Gastroenterol. 2009;104(1):154-163. doi:10.1038/ajg.2008.8 

​5. Penny HA, Raju SA, Lau MS, et al. Accuracy of a no-biopsy approach for the diagnosis of coeliac disease across different adult cohorts. Gut. 2021;70(5):876-883. doi:10.1136/gutjnl-2020-320913 

​ ​ 

2025 Platinum Partner 2025 Gold Partner 2025 Silver Sponsor More sponsors

Could It Be Celiac? Take the Symptom Checklist

Help us change
the lives of Gluten-Free Canadians.

thumb Donate thumb Volunteer thumb Partner

Get our monthly newsletter.

News, hot topics, tips, education & more.

Help support the CCA by visiting our shop.

All proceeds will go towards supporting Canadians with Celiac.

Have a question? Ask CCA!

    X
    QUESTIONS?